Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CORT
CORT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CORT News
Pomerantz LLP Investigates Securities Fraud Claims Against Corcept Therapeutics
3d ago
PRnewswire
Corcept's Treatment Faces FDA Warning, Shares Plummet
6d ago
PRnewswire
DJS Law Group Investigates Corcept for Securities Violations
6d ago
Newsfilter
Corcept Faces Investor Lawsuit Investigation
Feb 04 2026
Globenewswire
Corcept's Treatment Faces FDA Warning, Shares Plummet
Feb 04 2026
Globenewswire
Corcept Therapeutics Faces Investigation After FDA Rejection
Feb 03 2026
Businesswire
Pomerantz LLP Investigates Corcept for Securities Fraud
Feb 03 2026
Globenewswire
Corcept's Treatment Faces FDA Warning, Shares Plummet
Feb 02 2026
PRnewswire
DJS Law Group Investigates Corcept Securities Violations
Feb 02 2026
Newsfilter
Corcept Therapeutics Under Legal Investigation Following FDA Response
Feb 02 2026
Globenewswire
Corcept Therapeutics Faces FDA Warning Over Drug Efficacy Claims
Jan 31 2026
Businesswire
Corcept's Treatment Faces FDA Warnings, Shares Plunge
Jan 30 2026
Globenewswire
Berman Tabacco Investigates Corcept for Securities Violations
Jan 30 2026
Globenewswire
FDA Refuses Approval for Corcept's Relacorilant Drug
Jan 30 2026
stocktwits
Rosen Law Firm Investigates Securities Claims for Corcept Shareholders
Jan 30 2026
Businesswire
Corcept Therapeutics Faces FDA Setback on Drug Application
Jan 30 2026
Globenewswire
Show More News
